Azido- and chlorido-cobalt complex as carrier-prototypes for antitumoral prodrugs

Cobalt(III)-py2en systems as potential carriers of β-ketoester-based ligands

Two cobalt(III) complexes containing different β-ketoesters, namely [CoIII(L1)(py2en)](ClO4)2·H2O (1) and [CoIII(L2)(py2en)](ClO4)2 (2) (py2en = N,N'-bis(pyridin-2-ylmethyl)ethylenediamine; L1- = methylacetoacetate; L2- = ethyl 4-chloroacetoacetate) have been prepared and investigated as prototypes of bioreductive prodrugs. The presence of β-ketoester and py2en ligands in 1 and 2, as well as the perchlorate counterions, was supported by IR spectroscopy and CHN elemental analysis. The composition molecular structure of both complexes was confirmed by NMR spectroscopy and ESI mass spectrometry. Structural information was also obtained for 2via X-ray diffraction analysis. The redox properties indicate that 1 and 2 are suitable for reduction under biological conditions. Investigation of DNA-interacting suggest that 1 and 2 bind DNA via electrostatic forces. Both complexes may be employed as possible platforms for the delivery of biologically active compounds, since their reaction with ascorbic acid in PBS at pH 6.2 and 7.4 at 37°C results in the release of the β-ketoester ligands upon Co(III)/Co(II) reduction.

Valence tautomerism in a cobalt-dioxolene complex containing an imidazolic ancillary ligand

This work reports the synthesis, structural, spectroscopic and magnetic investigation of two complexes, [Co(bmimapy)(3,5-DTBCat)]PF₆·H₂O (1) and [Co(bmimapy)(TCCat)]PF₆·H₂O (2), where bmimapy is an imidazolic tetradentate ancillary ligand and 3,5-DTBCat and TCCat are the 3,5-di-tert-butyl-catecholate and tetrachlorocatecholate anions, respectively. Their structures have been elucidated using single crystal X-ray diffraction, showing a pseudo-octahedral cobalt ion bound to a chelating dioxolene ligand and the ancillary bmimapy ligand in a folded conformation. Magnetometry displayed an entropy-driven, incomplete, Valence Tautomeric (VT) process for 1 in the 300-380 K temperature range, while 2 displayed a temperature independent, diamagnetic low-spin cobalt(iii)-catecholate charge distribution. This behaviour was interpreted on the basis of the cyclic voltammetric analysis, allowing the estimation of the free energy difference associated with the VT interconversion of +8 and +96 kJ mol^-1 for 1 and 2, respectively. A DFT analysis of this free energy difference highlighted the ability of the methyl-imidazole pendant arm of bmimapy favouring the onset of the VT phenomenon. This work introduces the imidazolic bmimapy ligand to the scientific community working in the field of valence tautomerism, increasing the library of ancillary ligands to prepare temperature switchable molecular magnetic materials.

A bioinspired cobalt catalyst based on a tripodal imidazole/pyridine platform capable of water reduction and oxidation

The prototypical drug carrier [Co^II(L¹)Cl]PF₆ (1), where L¹ is a tripodal amine bound to pyridine and methyl-imidazoles, had its electrocatalytic water splitting activity studied under different pH conditions. This species contains a high-spin 3d⁷ Co^II metal center, and is capable of generating both H₂ from water reduction and O₂ from water oxidation_. Turnover numbers reach 390 after 3 h for water reduction. Initial water oxidation activity is molecular, with TONs of 71 at pH 7 and 103 at pH 11.5. The results reveal that species 1 can undergo several redox transformations, including reduction to the 3d⁸ Co^I species that precedes a ^LS3d⁶ hydride for water reduction, as well as nominal Co^IVO and Co^III-OOH species required for water oxidation. Post-catalytic analyses confirm the molecular nature of reduction and support initial molecular activity for oxidation.

Investigation of cobalt(III)-phenylalanine complexes for hypoxia-activated drug delivery

Four cobalt(iii)-phenylalanine complexes, [Co(Phe)(py2en)](ClO4)2·H2O (1), [Co(Phe)(TPA)](ClO4)2·H2O (2), [Co(Phe)(py2enMe2)](ClO4)2·H2O (3) and [Co(bipy)2(Phe)](ClO4)2·H2O (4), were investigated as prototype models for hypoxia-activated delivery of melphalan - a phenylalanine derivative anticancer drug of the class of nitrogen mustards. Single crystal X-ray diffraction analysis provided the molecular structures of 1-4, as a single isomer/conformer. According with NMR and theoretical calculations, the solid-state structures of 2 and 4 are maintained in solutions. For complexes 1 and 3, though, a mixture of isomers was found in DMSO solutions: Λ-cisα(exo,exo) and Δ-cisβ1(exo,exo) for 1 (3 : 2 ratio), and Λ-cisα(exo,exo) and Δ-cisα(exo,exo) for 3 (5 : 1 ratio). Theoretical calculations point to a re-equilibration reaction of the solid-state Λ-cisβ1 isomer of 1 in solution. Electrochemical analysis revealed a correlation between the electron-donor capacity of the ancillary ligands and the redox potentials of the complexes. The potentials varied from +0.01 for 1 to +0.31 V vs. SHE for 4 in aqueous media and indicate that reduction should be achieved in biological media. The integrity of the complexes in pH 5.5 and 7.4 buffered solutions was confirmed by UV-Vis monitoring up to 24 h at 25 °C. Reduction by ascorbic acid (AA) shows an O2-dependent dissociation of the l-Phe for complexes 1-3, with higher conversion rates at pH 7.4. For complex 4, a fast dissociation of l-Phe was observed, with conversion rates unaffected by the pH and presence of O2.

Evaluation of cobalt(III) complexes as potential hypoxia-responsive carriers of esculetin

Differentiation between hypoxic and normoxic tissues have been exploited for the development of selective chemotherapeutic agents. In this context, cobalt(III)-based coordination compounds have been designed and investigated as prospective hypoxia-responsive drug delivery systems. Three cobalt(III) complexes, namely [Co^III(esc)(py₂en)]ClO₄·(CH₃OH)₂ (1) [Co^III(esc)(TPA)]ClO₄·3H₂O (2) and [Co^III(bipy)₂(esc)]ClO₄·2.5H₂O (3) (py₂en = N,N'-bis(pyridin-2-ylmethyl)ethylenediamine, TPA = tris(2-pyridylmethyl)amine, bipy = 2,2'-bipyridine and esc = 6,7-dihydroxycoumarin or esculetin), were prepared and investigated as potential carriers of esculetin. The spectroscopic and electrochemical properties of 1-3 were investigated and compared. Reactions of the complexes with biologically relevant reducing agents, viz. ascorbic acid, cysteine and glutathione, were monitored spectroscopically for 24 h, in pH 6.2 and 7.4 PBS phosphate buffer saline (PBS) solutions at 37 °C, under air, argon and dioxygen atmospheres. Dissociation of esculetin was observed upon Co³⁺/Co²⁺ reduction preferably under hypoxic conditions, with more effective conversion rates for 3 > 2 > 1. These results illustrate the importance to modulate the Co³⁺/Co²⁺ redox potential through the donor-acceptor properties of the ancillary ligands. Complex 3 is cytotoxic against HCT-116 but not against HT-29 and HEK-293 cells. In addition, DNA-binding studies indicate that interactions of 1 and 3 with the biomolecule are electrostatic.

Transition Metal-Based Prodrugs for Anticancer Drug Delivery

:

Transition metal complexes, of which the platinum(II) complex cisplatin is an example, have been used in medicine to treat cancer for more than 40 years. Although many successes have been achieved, there are problems associated with the use of these drugs, such as side effects and drug resistance. Converting them into prodrugs, to make them more inert, so that they can travel to the tumour site unchanged and release the drug in its active form only there, is a strategy which is the subject of much research nowadays. The new prodrugs may be activated and release the cytotoxic agent by differences in oxygen concentration or in pH, by the action of overexpressed enzymes, by differences in metabolic rates, etc., which characteristically distinguish cancer cells from normal ones, or even by the input of radiation, which can be visible light. Converting a metal complex into a prodrug may also be used to improve its pharmacological properties. In some cases, the metal complex is a carrier which transports the active drug as a ligand. Some platinum prodrugs have reached clinical trials. So far platinum, ruthenium and cobalt have been the most studied metals. This review presents the recent developments in this area, including the types of complexes used, the mechanisms of drug action and in some cases the techniques applied to monitor drug delivery to cells.

An unusual partial occupancy of labile chloride and aqua ligands in cocrystallized isomers of a nickel(II) complex bearing a tripodal N4-donor ligand

A novel Ni²⁺ complex with the N₄-donor tripodal ligand bis[(1-methyl-1H-imidazol-2-yl)methyl][2-(pyridin-2-yl)ethyl]amine (L), namely, aqua{bis[(1-methyl-1H-imidazol-2-yl-κN³)methyl][2-(pyridin-2-yl-κN)ethyl]amine-κN}chloridonickel(II) perchlorate, [NiCl(C₁₇H₂₂N₆)(H₂O)]ClO₄ or [NiCl(H₂O)(L)Cl]ClO₄ (1), was synthesized and characterized by spectroscopic and spectrometric methods. The crystal structure of 1 reveals an interesting and unusual cocrystallization of isomeric complexes, which are crystallographically disordered with partial occupancy of the labile cis aqua and chloride ligands. The Ni²⁺ centre exhibits a distorted octahedral environment, with similar bond lengths for the two Ni-N(imidazole) bonds. The bond length increases for Ni-N(pyridine) and Ni-N(amine), which is in agreement with literature examples. The bond lengths of the disordered labile sites are also in the expected range and the Ni-Cl and Ni-O bond lengths are comparable with similar compounds. The electronic, redox and solution stability behaviour of 1 were also evaluated, and the data obtained suggest the maintenance of structural integrity, with no sign of demetalation or decomposition under the studied conditions.

Synthesis and Characterization of trans-Dichlorotetrakis(imidazole)cobalt(III) Chloride: A New Cobalt(III) Coordination Complex with Potential Prodrug Properties

Numerous therapies for the treatment of cancer have been explored with increasing evidence that the use of metal-containing compounds could prove advantageous as anticancer therapeutics. Previous works on Ru(III) complexes suggest that structurally similar Co(III) complexes may provide good alternative, low-cost, effective prodrugs. Herein, a new complex, trans-[Co(imidazole)₄Cl₂]Cl (2), has been synthesized in high yields utilizing ligand exchange under refluxing conditions. The structure of 2 has been characterized by elemental analysis, ¹H and ¹³C·NMR, ESI-MS, CV, and UV-Vis. The ability of 2 to become reduced in the presence of ascorbic acid was probed demonstrating the likely reduction of the Co(III) metal center to Co(II). In addition, preliminary cell line testing on 2 shows a lack of cytotoxicity.

Photoresponsive Drug/Gene Delivery Systems

Light as an external stimulus can be precisely manipulated in terms of irradiation time, site, wavelength, and density. As such, photoresponsive drug/gene delivery systems have been increasingly pursued and utilized for the spatiotemporal control of drug/gene delivery to enhance their therapeutic efficacy and safety. In this review, we summarized the recent research progress on photoresponsive drug/gene delivery, and two major categories of delivery systems were discussed. The first category is the direct responsive systems that experience photoreactions on the vehicle or drug themselves, and different materials as well as chemical structures responsive to UV, visible, and NIR light are summarized. The second category is the indirect responsive systems that require a light-generated mediator signal, such as heat, ROS, hypoxia, and gas molecules, to cascadingly trigger the structural transformation. The future outlook and challenges are also discussed at the end.

Is IQG-607 a Potential Metallodrug or Metallopro-Drug With a Defined Molecular Target in Mycobacterium tuberculosis?

The emergence of strains of Mycobacterium tuberculosis resistant to isoniazid (INH) has underscored the need for the development of new anti-tuberculosis agents. INH is activated by the mycobacterial katG-encoded catalase-peroxidase, forming an acylpyridine fragment that is covalently attached to the C4 of NADH. This isonicotinyl-NAD adduct inhibits the activity of 2-trans-enoyl-ACP(CoA) reductase (InhA), which plays a role in mycolic acid biosynthesis. A metal-based INH analog, Na₃[Fe^II(CN)₅(INH)]·4H₂O, IQG-607, was designed to have an electronic redistribution on INH moiety that would lead to an intramolecular electron transfer to bypass KatG activation. HPLC and EPR studies showed that the INH moiety can be oxidized by superoxide or peroxide yielding similar metabolites and isonicotinoyl radical only when associated to IQG-607, thereby supporting redox-mediated drug activation as a possible mechanism of action. However, IQG-607 was shown to inhibit the in vitro activity of both wild-type and INH-resistant mutant InhA enzymes in the absence of KatG activation. IQG-607 given by the oral route to M. tuberculosis-infected mice reduced lung lesions. Experiments using early and late controls of infection revealed a bactericidal activity for IQG-607. HPLC and voltammetric methods were developed to quantify IQG-607. Pharmacokinetic studies showed short half-life, high clearance, moderate volume of distribution, and low oral bioavailability, which was not altered by feeding. Safety and toxic effects of IQG-607 after acute and 90-day repeated oral administrations in both rats and minipigs showed occurrence of mild to moderate toxic events. Eight multidrug-resistant strains (MDR-TB) were resistant to IQG-607, suggesting an association between katG mutation and increasing MIC values. Whole genome sequencing of three spontaneous IQG-607-resistant strains harbored katG gene mutations. MIC measurements and macrophage infection experiments with a laboratorial strain showed that katG mutation is sufficient to confer resistance to IQG-607 and that the macrophage intracellular environment cannot trigger the self-activation mechanism. Reduced activity of IQG-607 against an M. tuberculosis strain overexpressing S94A InhA mutant protein suggested both the need for KatG activation and InhA as its target. Further efforts are suggested to be pursued toward attempting to translate IQG-607 into a chemotherapeutic agent to treat tuberculosis.

Novel CoIII complexes containing fluorescent coumarin-N-acylhydrazone hybrid ligands: Synthesis, crystal structures, solution studies and DFT calculations

A series of new Co^III complexes of the type [Co(dien)(L1-L3)]ClO₄ (1-3), containing fluorescent coumarin-N-acylhydrazonate hybrid ligands, (E)-N'-(1-(7-oxido-2-oxo-2H-chromen-3-yl)ethylidene)-4-R-benzohydrazonate [where R=H (L1^2-), OCH₃ (L2^2-) or Cl (L3^2-)], were obtained and isolated in the low spin Co^III configuration. Single-crystal X-ray diffraction showed that the coumarin-N-acylhydrazones act as tridentate ligands in their deprotonated form (L^2-). The cation (+1) complexes contain a diethylenetriamine (dien) as auxiliary ligand and their structures were calculated by DFT studies which were also performed for the Co^II (S=1/2 and S=3/2) configurations. The LS Co^II (S=1/2) concentrated the spin density on the O-Co-O axis while the HS Co^II (S=3/2) exhibited a broad spin density distribution around the metallic center. Cyclic voltammetry studies showed that structural modifications made in the L^2- ligands caused a slight influence on the electronic density of the metal center, and the E_1/2 values for the Co^III/Co^II redox couple increased following the electronic effect of the R-substituent, in the order: 2 (R=OCH₃)<1 (R=H)<3 (R=Cl). The theoretical redox potentials (E°) of the process Co^III→Co^II were calculated for both Co^II spin states (S=1/2 and S=3/2) and a better correlation was found for Co^III→Co^II (S=1/2), compared with experimental values vs SHE (E^°_calc=-0.37, -0.36 and -0.32V vs E^°_exp.=-0.371, -0.406 and -0.358V, for 1-3 respectively). Complexes 1-3 exhibited a very intense absorption band around 470nm, assigned by DFT calculations as π-π* transitions from the delocalized coumarin-N-acylhydrazone system. 1-3 were very stable in MeOH for several days. Likewise, 1-3 were stable in phosphate buffer containing sodium ascorbate after 15h, which was attributed to the high chelate effect and σ-donor ability of the L^2- and dien ligands.

Manipulating tumor hypoxia toward enhanced photodynamic therapy (PDT)

This mini-review summarizes various methods for overcoming or utilizing hypoxia for enhanced PDT.

Investigation of cobalt(iii)–TPA complexes as potential bioreductively activated carriers for naphthoquinone-based drugs

Differently from CH₃, halogens as substituents foster incorporation of methoxide into NQs upon complexation.

Investigation of cobalt(iii)-triazole systems as prototypes for hypoxia-activated drug delivery

A novel cobalt(iii)-triazole system was developed for hypoxia-activated drug delivery with an [O₂]-dependent reduction to cobalt(ii) followed by ligand dissociation.